

## Glioma

Recurrent

High Grade

Pre- Avastin

Surgical Procedural  
Candidates

BRAF Mutation

FGFR1-3  
Alteration

[BRN0048](#)  
[Phase I, First-In-Human, Multicenter, Open-Label Study of ABM-1310 Administered Orally in Adult Patients with Advanced Solid Tumors](#)

PI: Nagpal  
ABM Therapeutics, Inc.

**BRN0056**  
Phase I/II Dose-Escalation Study of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

PI: Nagpal  
VBI Vaccines Inc.

**BRN0054**  
Phase II Pemigatinib in Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

PI: Lim  
Incyte Corporation

**BRN0042**  
Phase II/III Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

PI: Recht  
Pending

[CCT5061](#)  
[Phase I Locoregionally \(LR\) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells \(B7-H3CART\) in Recurrent Glioblastoma Multiforme \(GBM\)](#)

PI: Thomas  
Stanford University




[BRN0045](#)  
[Phase I/II Exablate Type 2 for BBBD With Microbubble Resonators in Tx of rGBM in Carboplatin Mono Treatment](#)




PI: Nagpal  
InSightec, Inc.



**BRN0049**  
Phase Ib Nivolumab or the Combination Nivolumab + Ipilimumab in Surgically Accessible Glioblastoma

PI: Lim  
Pending

### KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
-  Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy